NewEdge Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

NewEdge Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45	Closed	-$673	–	4205
2025 Q3	$673	Hold	45	–	–	﹤0.01%	3918
2025 Q2	$524	Hold	45	–	–	﹤0.01%	3797
2025 Q1	$334	Hold	45	–	–	﹤0.01%	3758
2024 Q4	$270	Hold	45	–	–	﹤0.01%	3724
2024 Q3	$230	Hold	45	–	–	﹤0.01%	3673
2024 Q2	$163	Hold	45	–	–	﹤0.01%	3663
2024 Q1	$144	Sell	45 -10,000	-100%	-$38.7K	﹤0.01%	3689
2023 Q4	$49.2K	Sell	10,045 -14	-0.1%	-$64	﹤0.01%	2238
2023 Q3	$54.8K	Hold	10,059	–	–	﹤0.01%	2072
2023 Q2	$67.5K	Sell	10,059 -2,171	-18%	-$16.1K	﹤0.01%	1993
2023 Q1	$84K	Buy	12,230 +10,032	+456%	+$88.4K	﹤0.01%	1807
2022 Q4	$17	Buy	+2,198	New	+$17.1K	﹤0.01%	3621

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NewEdge Advisors's ADPT Position: Q4 2025 in Review

NewEdge Advisors sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 45 shares — an estimated $673 sold.

NewEdge Advisors first reported a position in ADPT in Q4 2022 and held it in 12 quarters. The position peaked at $84K in Q1 2023. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

NewEdge Advisors reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
NewEdge Advisors sold 45 Adaptive Biotechnologies shares in Q4 2025, an estimated $673.
NewEdge Advisors first reported a position in Adaptive Biotechnologies in Q4 2022 and held it in 12 quarters.
NewEdge Advisors's Adaptive Biotechnologies position peaked at $84K in Q1 2023.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.